SynthesisPloS one2024
Purtscher's and Purtscher-like retinopathy etiology, features, management, and outcomes: A summative systematic review of 168 cases.
Synthesis in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ocular manifestations of primary thrombotic microangiopathies : a descriptive systematic review.BMC ophthalmology · 2025Pooled it
- Purtscher-like retinopathy as a presenting ocular manifestation of biopsy-proven giant cell arteritis: A case report.The Journal of international medical research · 2026Article
- Long-Term Follow-Up in a Patient with Purtscher-Like Retinopathy Associated with Systemic Lupus Erythematosus: A Case Report.Korean journal of ophthalmology : KJO · 2026Article
- Article
- Optical Coherence Tomography Angiography Findings in Post-Traumatic Purtscher Retinopathy: A Case Report.The American journal of case reports · 2026Article
- Case Report: Monocular Purtscher-like retinopathy secondary to systemic lupus erythematosus: analysis of clinical characteristics under low disease activity.Frontiers in immunology · 2026Article
- Commentary: Case Report: CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation triggers Purtscher-like retinopathy: clinical features and complement-mediated microvascular injury mechanisms.Frontiers in immunology · 2026Article
- Purtscher-Like Retinopathy in a Young Male With Renal Failure Following Bodybuilding Supplement Overuse: A Case Report.Case reports in medicine · 2026Article
- Article
- Purtscher-like Retinopathy in a Patient with Acute Alcoholic Pancreatitis and a Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Case report: Purtscher-like Retinopathy in a Patient after otorhinolaryngological surgery.American journal of ophthalmology case reports · 2025Article
- Purtscher-like retinopathy following mechanical thrombectomy: A case report.SAGE open medical case reports · 2025Article
- Ophthalmic Manifestations Heralding Renal Pathology: A Rare Case of Bilateral Optic Disc Edema with Exudative Maculopathy in IgA Nephropathy.Case reports in ophthalmologyArticle
- Purtscher-Like Retinopathy with Renal Impairment: A Case Report and Review of the Literature.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo describe Purtscher's and Purtscher-like retinopathy clinical features, etiologies, management options, and visual outcomes.
methodsOur protocol was registered on PROSPERO [registration number: CRD42023406843]. Seven online databases were searched: PubMed, Scopus, Medline, ScienceDirect, CENTRAL, clinicaltrials.gov, and Google Scholar. Original articles were included if they reported at least one subject diagnosed with Purtscher's or Purtscher-like retinopathy. The primary outcome is to describe the clinical features of Purtscher and Purtscher-like retinopathies, including etiologies, results of related investigations, management lines, and visual outcomes. All analyses were conducted with the use of Statistical Package for Social Sciences (SPSS) version 27 (IBM SPSS Corp, SPSS Statistics ver. 26, USA) and Cochrane's RevMan software. The methodological quality of included studies was assessed using the NIH quality assessment tools.
resultsA total of 114 articles were included, describing 168 cases of Purtscher's and Purtscher-like retinopathy. Patients were evenly distributed between males (50.89%) and females (49.11%). Average age of patients was 34.62 years old. Trauma was the leading cause of retinopathy, being reported in 39.88% of our patients, followed by systemic lupus erythematosus (SLE) (13.1%) and acute pancreatitis (11.9%). Bilateral symptoms were reported in 57.7% of patients with centrally blurred vision being the most complained symptom (OS: 34.32% and OD: 18%). 75% of patients elicited bilateral retinal findings. Cotton-wool spots were of highest prevalence (58%). Purtscher flecken was seen in 53% of patients. Macular edema was seen in 13% of patients. Overall, patients had a favorable prognosis (53%).
conclusionPurtscher's and Purtscher-like retinopathies are rare sight-threatening retinopathies that develop most commonly following trauma or other systemic diseases as SLE and acute pancreatitis. Little data is available regarding these conditions, and available data is of low quality. Patients develop bilateral disease in approximately 50% of cases, and several retinal findings are observed, with no specific tendency. Most observed signs are cotton-wool spots in around 55% of patients and Purtscher flecken in 51% of patients. Patients spontaneously recovered, although data is not conclusive. No clear prognostic value of etiological factors is identified, and further research is required in this regard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.